

PATENT COOPERATION TREATY

From the
INTERNATIONAL SEARCHING AUTHORITY

PCT

To:

see form PCT/ISA/220

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY
(PCT Rule 43*bis*.1)

Date of mailing
(day/month/year) see form PCT/ISA/210 (second sheet)

Applicant's or agent's file reference
see form PCT/ISA/220

FOR FURTHER ACTION
See paragraph 2 below

International application No.
PCT/US2018/048878

International filing date (day/month/year)
30.08.2018

Priority date (day/month/year)
30.08.2017

International Patent Classification (IPC) or both national classification and IPC
INV. A61M5/20 A61M5/142

Applicant
PIROUETTE MEDICAL LLC

1. This opinion contains indications relating to the following items:

- Box No. I Basis of the opinion
- Box No. II Priority
- Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- Box No. IV Lack of unity of invention
- Box No. V Reasoned statement under Rule 43*bis*.1(a)(i) with regard to novelty, inventive step and industrial applicability; citations and explanations supporting such statement
- Box No. VI Certain documents cited
- Box No. VII Certain defects in the international application
- Box No. VIII Certain observations on the international application

2. **FURTHER ACTION**

If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1*bis*(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

Name and mailing address of the ISA:



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0
Fax: +49 89 2399 - 4465

Date of completion of
this opinion

see form
PCT/ISA/210

Authorized Officer

Neiller, Frédéric

Telephone No. +49 89 2399-0



Box No. I Basis of the opinion

1. With regard to the **language**, this opinion has been established on the basis of:
 - the international application in the language in which it was filed.
 - a translation of the international application into , which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1 (b)).
2. This opinion has been established taking into account the **rectification of an obvious mistake** authorized by or notified to this Authority under Rule 91 (Rule 43bis.1(a))
3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, this opinion has been established on the basis of a sequence listing:
 - a. forming part of the international application as filed:
 - in the form of an Annex C/ST.25 text file.
 - on paper or in the form of an image file.
 - b. furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
 - c. furnished subsequent to the international filing date for the purposes of international search only:
 - in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
 - on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
4. In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
5. Additional comments:

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of

the entire international application

claims Nos. 25-38

because:

the said international application, or the said claims Nos. relate to the following subject matter which does not require an international search (*specify*):

the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed (*specify*):

no international search report has been established for the whole application or for said claims Nos. 25-38

a meaningful opinion could not be formed without the sequence listing; the applicant did not, within the prescribed time limit:

furnish a sequence listing in the form of an Annex C/ST.25 text file, and such listing was not available to the International Searching Authority in the form and manner acceptable to it; or the sequence listing furnished did not comply with the standard provided for in Annex C of the Administrative Instructions.

furnish a sequence listing on paper or in the form of an image file complying with the standard provided for in Annex C of the Administrative Instructions, and such listing was not available to the International Searching Authority in the form and manner acceptable to it; or the sequence listing furnished did not comply with the standard provided for in Annex C of the Administrative Instructions.

pay the required late furnishing fee for the furnishing of a sequence listing in response to an invitation under Rule 13ter.1(a) or (b).

See Supplemental Box for further details

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims	<u>8, 9</u>
	No: Claims	<u>1-7, 10-24</u>
Inventive step (IS)	Yes: Claims	<u>8, 9</u>
	No: Claims	<u>1-7, 10-24</u>
Industrial applicability (IA)	Yes: Claims	<u>1-24</u>
	No: Claims	

2. Citations and explanations

see separate sheet

Re Item III:

- 1 Claim 25 discloses a method of operating an auto-injector comprising the steps of deploying a needle in a patient (treatment by surgery) and dispensing a dose to a patient (treatment by therapy).

According to Rule 39.1(iv) PCT, methods for treatment of the human or animal body by therapy or surgery are not patentable.

Therefore, claim 25 and its dependent claims 26-38 have been ignored.

Re Item V:

- 2 Reference is made to the following document:

D1 WO 2017/004315 A1 (VALERITAS INC [US]) 5 January 2017
(2017-01-05)

- 3 Claim 1 does not meet the requirements of Article 6 PCT because the matter for which protection is sought is not clearly defined. The claim attempts to define the subject-matter in terms of the result to be achieved (...comprising a curved injection needle adapted to be straightened during deployment...), which merely amounts to a statement of the underlying problem, without providing the technical features necessary for achieving this result. What are the technical features used to straighten the needle during its deployment?
The technical features of claims 2, 3, 4, 5 and 8 would solve the problem and explain more in details the features used in the functioning of the device.

4 CLAIM 1

The document D1 discloses (the references in parentheses applying to this document):

device for delivering a medicament dose subcutaneously or intramuscularly, the device comprising: a housing (112); a medicament dispensing system disposed within the housing (112) and comprising a medicament reservoir (222) adapted to contain the dose; and a needle extension mechanism coupled to the medicament reservoir (222), the needle extension mechanism comprising a curved injection needle (430) adapted to be straightened during deployment of the needle to facilitate dispensing of the dose by the auto-injector.

The subject-matter of claim 1 is therefore not new (Article 33(2) PCT).

The device of D1 is not an auto-injector as claimed in claim 1, but nevertheless comprises all the technical features (housing, reservoir, needle...).

5 DEPENDENT CLAIMS 2-24

5.1 The features of claims 2-7 and 10-24 are merely one of several straightforward possibilities from which the skilled person would select, in accordance with circumstances, without the exercise of inventive skill, in order to solve the problem posed.

5.2 The combination of the features of claims 1, 2, 3, 4, 5 and 8 is neither known from, nor rendered obvious by, the available prior art.

A new claim 1 based on original claims 1, 2, 3, 4, 5 and 8 would appear to meet the requirements of Articles 6, 33(2) and 33(3) PCT.

- 6 Any new independent claim 1 would have to be worded in the two-part form in accordance with Rule 6.3(b) PCT, which in the present case would be appropriate, with those features known in combination from the prior art being placed in the preamble (Rule 6.3(b)(i) PCT) and the remaining features being included in the characterising part (Rule 6.3(b)(ii) PCT).
- 7 The features of the claims are not provided with reference signs placed in parentheses (Rule 6.2(b) PCT).